Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2026)

Roivant Sciences (ROIV) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$290.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 6.1% year-over-year to -$290.6 million; the trailing twelve-month figure through Jun 2026 stood at -$1.5 billion (down 157.62% YoY), and the FY2026 full-year result was -$397.9 million, down 11.59% from the prior year.
• Net Income towards Common Stockholders grew to -$290.6 million in Q2 2026 per ROIV's latest filing, from -$753.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $4.9 billion in Q4 2023 and bottomed at -$1.1 billion in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged $56.1 million across 5 years, with a median of -$290.6 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders surged 564.5% in 2023, then slumped 844.63% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$1.1 billion in 2022, then soared by 564.5% to $4.9 billion in 2023, then slumped by 101.63% to -$79.8 million in 2024, then plunged by 844.63% to -$753.7 million in 2025, then jumped by 61.44% to -$290.6 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$290.6 million, -$753.7 million, and -$166.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.